- Previous Close
3.0100 - Open
3.0050 - Bid 2.9350 x --
- Ask 2.9400 x --
- Day's Range
2.9050 - 3.0250 - 52 Week Range
1.8886 - 17.9800 - Volume
440,849 - Avg. Volume
679,719 - Market Cap (intraday)
281.994M - Beta (5Y Monthly) 1.03
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6100 - Earnings Date Feb 7, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.25
Ascelia Pharma AB (publ), a biotech company, focuses on orphan oncology treatments in Sweden. The company identifies, develops, and commercializes novel drugs to address unmet needs for rare cancer conditions. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 trial for the treatment of gastric cancer. Ascelia Pharma AB (publ) was incorporated in 1999 and is based in Malmö, Sweden.
www.ascelia.comRecent News: ACE.ST
View MorePerformance Overview: ACE.ST
Trailing total returns as of 11/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACE.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACE.ST
View MoreValuation Measures
Market Cap
289.20M
Enterprise Value
220.10M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.69
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.82%
Return on Equity (ttm)
-64.84%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-62.3M
Diluted EPS (ttm)
-0.6100
Balance Sheet and Cash Flow
Total Cash (mrq)
95.72M
Total Debt/Equity (mrq)
24.74%
Levered Free Cash Flow (ttm)
-25.83M